Sanofi to buy Bioverativ, Biogen's hemophilia spinout, for $11.6B
January 22, 2018 at 07:06 AM EST
The deal is one of the largest struck by Sanofi in years, and marks its latest aggressive push into the market for hemophilia drugs.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.